Heparin and platelets are discouraged as treatment for patients who develop blood clots in the brain and low platelet counts 6-15 days after receiving Johnson & Johnson’s Janssen COVID-19 vaccine, following a clinical investigation review of 12 U.S. cases conducted by the CDC and institutions including Vanderbilt University Medical Center.

The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.

Vanderbilt University Medical Center is participating in a national phase 1 clinical trial in healthy adults of an investigational vaccine against the B.1.351 variant of the COVID-19 virus that was first identified in South Africa.

The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.

Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus.

Monroe Carell Jr. Children’s Hospital at Vanderbilt is set to begin a phase 2/3 clinical trial to study the safety and efficacy of the Moderna COVID-19 vaccine in children.

Vanderbilt University Medical Center is recruiting volunteers for a randomized controlled phase 2 clinical trial to help determine the prevalence of systemic allergic reactions (SARS) to the two-dose COVID-19 mRNA vaccines made by Pfizer-BioNTech and Moderna.